Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment
- 18 September 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 109 (1) , 122-129
Abstract
Vascular endothelial growth factor-A is widely used in clinical trials for the treatment of cardiac ischemia. VEGF-A was recently suggested to act in a proinflammatory manner, which could aggravate adjacent atherogenesis in VEGF-A–based therapy. To assess potential bystander effects, VEGF-A was focally overexpressed in advanced atherosclerotic plaques in ApoE−/− mice. Sheer-induced carotid artery plaques were transluminally incubated with Ad.hVEGF-A leading to neointimal overexpression of VEGF-A. Ad.hVEGF-A treatment of pre-existing lesions was seen to promote plaque expansion, with a concomitant increase in macrophage and lipid content, whereas it lowered collagen content. In general, Ad.hVEGF-A–treated plaques displayed a more vulnerable phenotype. VEGF-A overexpression was not accompanied by increased microvessel development in the neointima, suggesting that VEGF-A destabilizes atherosclerotic plaques through an angiogenesis-independent mechanism. Intravital microscopy confirmed that treatment with Ad.hVEGF-A led to an increased monocyte adhesion, which was mediated by a VCAM-1/PECAM-1–dependent pathway. VEGF-A indeed induced a differential expression of VCAM-1 and PECAM-1 in endothelial cells. Our data underline the importance of regular monitoring of stenotic vessels adjacent to the site of VEGF-A application. We propose that VCAM-1/PECAM-1–directed cotherapy may be an efficient strategy to prevent bystander effects of focal VEGF-A therapy in patients suffering from cardiovascular disease.Keywords
This publication has 44 references indexed in Scilit:
- Importance of Junctional Adhesion Molecule-A for Neointimal Lesion Formation and Infiltration in Atherosclerosis-Prone MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Gene Transfers of Vascular Endothelial Growth Factor-A, Vascular Endothelial Growth Factor-B, Vascular Endothelial Growth Factor-C, and Vascular Endothelial Growth Factor-D Have No Effects on Atherosclerosis in Hypercholesterolemic Low-Density Lipoprotein-Receptor/Apolipoprotein B48-Deficient MiceCirculation, 2005
- Overexpression of IL-18 Decreases Intimal Collagen Content and Promotes a Vulnerable Plaque Phenotype in Apolipoprotein-E–Deficient MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Arteriogenesis: Lessons Learned from Clinical TrialsEndothelium, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Clinical trials of gene therapy for atherosclerotic cardiovascular diseaseCurrent Opinion in Lipidology, 2002
- Vascular Endothelial Growth Factor–Induced Genes in Human Umbilical Vein Endothelial CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Atherosclerotic Lesions Grow Through Recruitment and Proliferation of Circulating Monocytes in a Murine ModelThe American Journal of Pathology, 2002
- Vascular Endothelial Growth Factor Is Necessary in the Development of Arteriosclerosis by Recruiting/Activating Monocytes in a Rat Model of Long-Term Inhibition of Nitric Oxide SynthesisCirculation, 2002
- Transendothelial Migration of Monocytes in Rat Aorta: Distribution of F-actin, α-Catenin, LFA-1, and PECAM-1Biotechnic & Histochemistry, 1999